1. Roob JM, Rabold T, Hayn T, Khoschsorur G, Resch U, Holzer H, Winklhofer-Roob BM (2001) Ex vivo low-density lipoprotein oxidizability and in vivo lipid peroxidation in patients on CAPD. Kidney Int 78S:128–136 Suppl
2. Van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, Van Leusen R (2003) Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C reactive protein and in vivo oxidized LDL. J Nephrol 16:238–244
3. Locatelli F, Del Vecchio L, Manzoni C (1998) Morbidity and mortality on maintenance haemodialysis. Nephron 80:380–400
4. Van Kuijk JP, Flu WJ, Chonchol M, Welten GMJM, Verhagen HJM, Bax JJ, Poldermans D (2010) The prevalence and prognostic implications of polyvascular atherosclerotic disease in patients with chronic kidney disease. Nephrol Dial Transplant 25:1882–1888
5. Junyent M, Martinez M, Borras M, Bertriu A, Coll B, Craver L, Marco MP, Sarró F, Valdivieso JM, Fernanadez E (2010) Usefulness of imaging techniques and novel biomarkers in the prediction of cardiovascular risk in patients with chronic kidney disease in Spain: the NEFRONA project. Nefrologia 30:119–126